Research & Literature

Defining early mycosis fungoides: validation of a diagnostic algorithm proposed by the International Society for Cutaneous Lymphomas.

Vandergriff T, Nezafati KA, Susa J, et al.

Journal of cutaneous pathology 2015; (42(5)):318-28 doi:10.1111/cup.12470.

Choosing a systemic treatment for advanced stage cutaneous T-cell lymphoma: mycosis fungoides and Sézary syndrome.

Duvic M

Hematology. American Society of Hematology. Education Program 2015; (2015()):529-44 doi:10.1182/asheducation-2015.1.529.

Past, present and future of cutaneous lymphomas.

Cerroni L

Seminars in diagnostic pathology 2017; (34(1)):3-14 doi:10.1053/j.semdp.2016.11.001.

Maintenance phase in psoralen-ultraviolet A phototherapy of early-stage mycosis fungoides. A critically appraised topic.

Grandi V, Delfino C, Pileri A, Pimpinelli N

The British journal of dermatology 2017; (177(2)):406-410 doi:10.1111/bjd.15302.

Psoralen with ultraviolet A-induced apoptosis of cutaneous lymphoma cell lines is augmented by type I interferons via the JAK1-STAT1 pathway.

Liszewski W, Naym DG, Biskup E, Gniadecki R

Photodermatology, photoimmunology & photomedicine 2017; (33(3)):164-171 doi:10.1111/phpp.12302.

Management Strategies for Mycosis Fungoides in India.

Raychaudhury T

Indian journal of dermatology 2017; (62(2)):137-141 doi:10.4103/ijd.IJD_71_17.

Circulating and skin-derived Sézary cells: clonal but with phenotypic plasticity.

Roelens M, Delord M, Ram-Wolff C, et al.

Blood 2017; (130(12)):1468-1471 doi:10.1182/blood-2017-03-772996.

U.K. national audit of extracorporeal photopheresis in cutaneous T-cell lymphoma.

Sanyal S, Child F, Alfred A, et al.

The British journal of dermatology 2018; (178(2)):569-570 doi:10.1111/bjd.15871.

Monoclonal antibodies against cutaneous T-cell lymphomas.

Alaibac M

Expert opinion on biological therapy 2017; (17(12)):1503-1510 doi:10.1080/14712598.2017.1369951.

Blood classification and blood response criteria in mycosis fungoides and Sézary syndrome using flow cytometry: recommendations from the EORTC cutaneous lymphoma task force.

Scarisbrick JJ, Hodak E, Bagot M, et al.

European journal of cancer (Oxford, England : 1990) 2018; (93()):47-56 doi:10.1016/j.ejca.2018.01.076.

Sézary syndrome-clinical and histopathologic features, differential diagnosis, and treatment.

Spicknall KE

Seminars in cutaneous medicine and surgery 2018; (37(1)):18-23 doi:10.12788/j.sder.2018.005.

New Therapies and Immunological Findings in Cutaneous T-Cell Lymphoma.

Fujii K

Frontiers in oncology 2018; (8()):198 doi:10.3389/fonc.2018.00198.

Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial.

Kim YH, Bagot M, Pinter-Brown L, et al.

The Lancet. Oncology 2018; (19(9)):1192-1204 doi:10.1016/S1470-2045(18)30379-6.

The PROCLIPI international registry of early-stage mycosis fungoides identifies substantial diagnostic delay in most patients.

Scarisbrick JJ, Quaglino P, Prince HM, et al.

The British journal of dermatology 2019; (181(2)):350-357 doi:10.1111/bjd.17258.

Naïve/memory T-cell phenotypes in leukemic cutaneous T-cell lymphoma: Putative cell of origin overlaps disease classification.

Horna P, Moscinski LC, Sokol L, Shao H

Cytometry. Part B, Clinical cytometry 2019; (96(3)):234-241 doi:10.1002/cyto.b.21738.

Mogamulizumab: a new tool for management of cutaneous T-cell lymphoma.

Ollila TA, Sahin I, Olszewski AJ

OncoTargets and therapy 2019; (12()):1085-1094 doi:10.2147/OTT.S165615.

Skin Directed Therapy in Cutaneous T-Cell Lymphoma.

Tarabadkar ES, Shinohara MM

Frontiers in oncology 2019; (9()):260 doi:10.3389/fonc.2019.00260.

Characteristics associated with significantly worse quality of life in mycosis fungoides/Sézary syndrome from the Prospective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) study.

Molloy K, Jonak C, Woei-A-Jin FJSH, et al.

The British journal of dermatology 2020; (182(3)):770-779 doi:10.1111/bjd.18089.

An Elusive Case of Mycosis Fungoides: Case Report and Review of the Literature.

Pallazola VA, Deib G, Abha S, et al.

Journal of general internal medicine 2019; (34(11)):2669-2674 doi:10.1007/s11606-019-05231-z.

A histo-immunopathologic and prognostic study of erythrodermic cutaneous T-cell lymphoma.

Vonderheid EC, Kantor GR, Telang GH, et al.

Journal of cutaneous pathology 2019; (46(12)):913-924 doi:10.1111/cup.13564.

Mogamulizumab Forecast: Clearer Patients, with a Slight Chance of Immune Mayhem.

Larocca C, Kupper TS, LeBoeuf NR

Clinical cancer research : an official journal of the American Association for Cancer Research 2019; (25(24)):7272-7274 doi:10.1158/1078-0432.CCR-19-2742.

Early-stage Mycosis Fungoides: Epidemiology and Prognosis.

Maguire A, Puelles J, Raboisson P, et al.

Acta dermato-venereologica 2020; (100(1)):adv00013 doi:10.2340/00015555-3367.

It is time to adopt a multicolor immunophenotyping approach to evaluate blood for Sézary syndrome and mycosis fungoides.

Craig FE

Cytometry. Part B, Clinical cytometry 2021; (100(2)):125-128 doi:10.1002/cyto.b.21872.

Current measures are not sufficient: an interview-based qualitative assessment of quality of life in cutaneous T-cell lymphoma.

Bhat TS, Herbosa CM, Rosenberg AR, et al.

The British journal of dermatology 2021; (184(2)):310-318 doi:10.1111/bjd.19298.

Sézary syndrome and mycosis fungoides: An overview, including the role of immunophenotyping.

Pulitzer MP, Horna P, Almeida J

Cytometry. Part B, Clinical cytometry 2021; (100(2)):132-138 doi:10.1002/cyto.b.21888.

Utility of flow cytometry and gene rearrangement analysis in tissue and blood of patients with suspected cutaneous T‑cell lymphoma.

Gibbs JD, Ma S, Kim A, et al.

Oncology reports 2021; (45(1)):349-358 doi:10.3892/or.2020.7865.

C6 Ceramide (d18:1/6:0) as a Novel Treatment of Cutaneous T Cell Lymphoma.

Wilhelm R, Eckes T, Imre G, et al.

Cancers 2021; (13(2)) doi:10.3390/cancers13020270.

Mogamulizumab-induced interface dermatitis drug rash treated successfully with methotrexate and extracorporeal photopheresis in a patient with Sézary syndrome.

Breen ID, Brumfiel CM, Patel MH, et al.

JAAD case reports 2021; (9()):24-27 doi:10.1016/j.jdcr.2020.12.035.

Clinicoprognostic implications of head and neck involvement by mycosis fungoides: A retrospective cohort study.

Jung JM, Yoo H, Lim DJ, et al.

Journal of the American Academy of Dermatology 2022; (86(6)):1258-1265 doi:10.1016/j.jaad.2021.03.056.

Phototherapy as a treatment of early-stage mycosis fungoides and predictive factors for disease recurrence: A 17-year retrospective study.

Rattanakaemakorn P, Ploydaeng M, Udompanich S, et al.

Indian journal of dermatology, venereology and leprology 2021; (87(5)):645-650.

Mycosis fungoides and Sézary syndrome: focus on the current treatment scenario.

Sanches JA, Cury-Martins J, Abreu RM, et al.

Anais brasileiros de dermatologia 2021; (96(4)):458-471 doi:10.1016/j.abd.2020.12.007.

Cutaneous T cell lymphoma.

Dummer R, Vermeer MH, Scarisbrick JJ, et al.

Nature reviews. Disease primers 2021; (7(1)):61 doi:10.1038/s41572-021-00296-9.

Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician's choice in cutaneous T-cell lymphoma: final data.

Horwitz SM, Scarisbrick JJ, Dummer R, et al.

Blood advances 2021; (5(23)):5098-5106 doi:10.1182/bloodadvances.2021004710.

Non-Hodgkin Lymphoma: Examining Mycosis Fungoides and Sézary Syndrome in the Context of Oncology Nursing.

Ow KV, Brant JM

Clinical journal of oncology nursing 2021; (25(5)):555-562 doi:10.1188/21.CJON.555-562.

Disseminated mature T-cell phenotype CD4/CD8 double-negative mycosis fungoides with pleural involvement.

Kasinathan G, Sathar J

Hematology, transfusion and cell therapy 2022; (44(4)):606-611 doi:10.1016/j.htct.2021.07.004.

Real-world effectiveness of brentuximab vedotin in the treatment of CD30-positive cutaneous T-cell lymphoma: a single-centre retrospective review.

Henderson Berg MH, Davison K, Popradi G

The British journal of dermatology 2022; (186(2)):379-381 doi:10.1111/bjd.20786.

Primary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTC.

Olsen EA, Whittaker S, Willemze R, et al.

Blood 2022; (140(5)):419-437 doi:10.1182/blood.2021012057.

Pathogenesis of cutaneous T cell lymphoma: Involvement of Staphylococcus aureus.

Fujii K

The Journal of dermatology 2022; (49(2)):202-209 doi:10.1111/1346-8138.16288.

Mogamulizumab induces long-term immune restoration and reshapes tumour heterogeneity in Sézary syndrome.

Roelens M, de Masson A, Andrillon A, et al.

The British journal of dermatology 2022; (186(6)):1010-1025 doi:10.1111/bjd.21018.

The Skin Microbiome and Influencing Elements in Cutaneous T-Cell Lymphomas.

Jost M, Wehkamp U

Cancers 2022; (14(5)) doi:10.3390/cancers14051324.

Intraindividual variability of CD30 expression in mycosis fungoides -implications for diagnostic evaluation and therapy.

Mitteldorf C, Kampa F, Ströbel P, et al.

Histopathology 2022; (81(1)):55-64 doi:10.1111/his.14660.

"Knock Me Out": The Challenges of Managing Pain Due to Cutaneous T Cell Lymphomas: A Case Report.

Pandey S, Dolan A, Norton-Westbrook M, Desai AV

Journal of palliative medicine 2022; (25(11)):1740-1746 doi:10.1089/jpm.2021.0561.

Application of the current diagnostic algorithm for early mycosis fungoides to a single center cohort: Identification of challenges and suggestions for modification.

Krishnasamy S, Correia E, Kartan S, et al.

Journal of cutaneous pathology 2022; (49(9)):772-779 doi:10.1111/cup.14243.

Cutaneous T-cell lymphoma: diagnosing subtypes and the challenges.

Hague C, Farquharson N, Menasce L, et al.

British journal of hospital medicine (London, England : 2005) 2022; (83(4)):1-7 doi:10.12968/hmed.2021.0149.

Activity and safety of topical pimecrolimus in patients with early stage mycosis fungoides (PimTo-MF): a single-arm, multicentre, phase 2 trial.

Ortiz-Romero PL, Maroñas Jiménez L, Muniesa C, et al.

The Lancet. Haematology 2022; (9(6)):e425-e433 doi:10.1016/S2352-3026(22)00107-7.

Serum cell-free DNA as a new biomarker in cutaneous T-cell lymphoma.

Mizuno Y, Shibata S, Miyagaki T, et al.

The Journal of dermatology 2022; (49(11)):1124-1130 doi:10.1111/1346-8138.16520.

Chlormethine Gel for the Treatment of Mycosis Fungoides Cutaneous T-Cell Lymphoma: In Vitro Release and Permeation Testing.

Giuliano C, Frizzarin S, Alonzi A, et al.

Dermatology and therapy 2022; (12(11)):2517-2529 doi:10.1007/s13555-022-00813-y.

Understanding itch in cutaneous T-cell lymphoma: Exploring the impact of comorbidities, treatment regimens, and racial differences on quality of life.

Joshi TP, Duvic M

JAAD international 2023; (10()):55-56 doi:10.1016/j.jdin.2022.11.006.

Multidisciplinary Approach to the Diagnosis and Therapy of Mycosis Fungoides.

Vitiello P, Sagnelli C, Ronchi A, et al.

Healthcare (Basel, Switzerland) 2023; (11(4)) doi:10.3390/healthcare11040614.

Mycosis fungoides and Sézary syndrome: clinical presentation, diagnosis, staging, and therapeutic management.

Miyashiro D, Sanches JA

Frontiers in oncology 2023; (13()):1141108 doi:10.3389/fonc.2023.1141108.

Cutaneous T-cell lymphoma-Focus on some problems, and some solutions.

Beltraminelli H

Hematological oncology 2023; (41 Suppl 1()):20-24 doi:10.1002/hon.3147.

Epidemiology of mature T/NK-cell lymphomas in Germany - A representative cross-sectional study based on SHI claims data.

Assaf C, Dobos G, Zech IM, et al.

Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG 2023; (21(11)):1320-1327 doi:10.1111/ddg.15187.

Utility of T-cell immunosequencing in distinguishing mycosis fungoides progression from treatment related cutaneous adverse events.

Bhatti S, Joffe D, Banner L, et al.

Frontiers in medicine 2023; (10()):1243459 doi:10.3389/fmed.2023.1243459.

Five paediatric patients with mycosis fungoides and our approach to provide age-appropriate information and psychological support.

Melchionda V, Ieremia E, Matin R, McPherson T

Clinical and experimental dermatology 2024; (49(5)):497-501 doi:10.1093/ced/llad457.

Mogamulizumab Combined with Extracorporeal Photopheresis as a Novel Therapy in Erythrodermic Cutaneous T-cell Lymphoma.

Ninosu N, Melchers S, Kappenstein M, et al.

Cancers 2023; (16(1)) doi:10.3390/cancers16010141.

Health-related quality of life and its influencing factors in patients with primary cutaneous B-cell lymphomas: A multicentric study in 100 patients.

Schirren AEC, Albrecht JD, Melchers S, et al.

Journal of the European Academy of Dermatology and Venereology : JEADV 2024; (38(5)):954-966 doi:10.1111/jdv.19799.

Phase I/II clinical trial of brentuximab vedotin for pretreated Japanese patients with CD30-positive cutaneous T-cell lymphoma.

Hirai Y, Sakurai J, Yoshida S, et al.

The Journal of dermatology 2024; (51(8)):1037-1049 doi:10.1111/1346-8138.17324.

Coexistence of large cell transformed mycosis fungoides and diffuse large B-cell lymphoma in one patient.

Rohan TZ, Suriano J, Tekmen V, et al.

Journal of cutaneous pathology 2024; (51(10)):761-766 doi:10.1111/cup.14673.

Characterization of cells and mediators associated with pruritus in primary cutaneous T-cell lymphomas.

Hu M, Scheffel J, Frischbutter S, et al.

Clinical and experimental medicine 2024; (24(1)):171 doi:10.1007/s10238-024-01407-y.

Systemic treatments with monoclonal antibodies in mycosis fungoides and Sézary syndrome.

Ibatici A, Angelucci E, Massone C

Dermatology reports 2024; (16(Suppl 2)):9970 doi:10.4081/dr.2024.9970.

Radiation therapy for a case of poikilodermatous plaques in an otherwise healthy young man: A case report.

Biba U, Poppens MJ, Collier EK, Cheng K

SAGE open medical case reports 2024; (12()):2050313X241274837 doi:10.1177/2050313X241274837.

The Tumor Microenvironment as a Therapeutic Target in Cutaneous T Cell Lymphoma.

Kwantwi LB, Rosen ST, Querfeld C

Cancers 2024; (16(19)) doi:10.3390/cancers16193368.

Skin barrier dysfunction in cutaneous T-cell lymphoma: From pathogenic mechanism of barrier damage to treatment.

Wen P, Zhuo X, Wang L

Critical reviews in oncology/hematology 2025; (205()):104559 doi:10.1016/j.critrevonc.2024.104559.

Case report: Canadian consensus on chlormethine gel use in mycosis fungoides-CTCL: literature review and real-world experience.

Litvinov IV, Abu-Hilal M, Alhusayen R, et al.

Frontiers in medicine 2024; (11()):1474030 doi:10.3389/fmed.2024.1474030.

Hypopigmented mycosis fungoides: an important differential diagnosis of hypochromias in childhood.

Aranha MFAC, Santos MALD, Pires CAA, et al.

Revista paulista de pediatria : orgao oficial da Sociedade de Pediatria de Sao Paulo 2025; (43()):e2024181 doi:10.1590/1984-0462/2025/43/2024181.

Haematopoietic stem cell transplant in cutaneous T-cell lymphomas: A multicentre propensity-score matched study.

Bejarano L, Grau-Pérez M, Paíno-Román M, et al.

Journal of the European Academy of Dermatology and Venereology : JEADV 2026; (40(1)):99-108 doi:10.1111/jdv.20638.

Fatal mycosis fungoides, misdiagnosed as contact dermatitis.

Shadmani G, Dumrongkulraksa J, Jahromi AH

EJNMMI reports 2025; (9(1)):15 doi:10.1186/s41824-025-00249-5.

Cutaneous T Cell Lymphoma Following Dupilumab Therapy in Patients with Atopic Dermatitis: Clinical Review and Recommendations.

Lavin L, Geller S

American journal of clinical dermatology 2025; (26(5)):723-731 doi:10.1007/s40257-025-00955-7.

Prognosis of increasing percentages of lesional body surface area in early stage mycosis fungoides.

Kersten JM, Ottevanger R, Quint KD, et al.

Journal of the European Academy of Dermatology and Venereology : JEADV 2026; (40(1)):116-121 doi:10.1111/jdv.20773.

Mycosis fungoides: a review.

Sheern C, Levell NJ, Craig PJ, et al.

Clinical and experimental dermatology 2025; (50(12)):2365-2375 doi:10.1093/ced/llaf341.

The Overlapping Clinicopathological Presentations of Pityriasis Lichenoides and Mycosis Fungoides.

Pierog O, Estill M, Jedrych J, et al.

Journal of cutaneous pathology 2025; (52(12)):785-794 doi:10.1111/cup.14856.

Allogeneic haematopoietic cell transplant in cutaneous T-cell lymphomas: Recommendations from the EBMT PH&G Committee.

Damaj G, de Masson A, Dreger P, et al.

Journal of the European Academy of Dermatology and Venereology : JEADV 2025; doi:10.1111/jdv.70042.

Histopathological Patterns in Mycosis Fungoides: A Cross-Sectional Study.

Mohaghegh F, Shayan M, Rajabi P, et al.

Journal of skin cancer 2025; (2025()):9995443 doi:10.1155/jskc/9995443.

Early nail involvement in mycosis fungoides with rapid systemic progression: rethinking the role of Ki-67: a case report.

Ali Asgarzadeh S, Beheshti AA

Journal of medical case reports 2025; (19(1)):560 doi:10.1186/s13256-025-05582-8.

Prevalence and Severity of Sleep Disorders in Patients With Mycosis Fungoides: A Case-Control Study.

Vafaeian A, Shahilooy A, Daneshpazhooh M, et al.

Journal of skin cancer 2025; (2025()):5528328 doi:10.1155/jskc/5528328.

How I manage mycosis fungoides and Sézary syndrome: Current controversies and unmet needs.

Stadler R, Quaglino P, Roccuzzo G

British journal of haematology 2026; (208(3)):864-873 doi:10.1111/bjh.70308.